Association of CD14 -260 (-159) C>Tand asthma: a systematic review and meta-analysis

BMC Medical Genetics

Table 2 Estimated ORs for CD14 -260 (-159) C>T and asthma.

	No. of studies	ORs (95% CI)			I ²(%) ^a			Suggested genetic model
		TT vs. CC (OR₁)	CT vs. CC (OR₂)	TT vs. CT (OR₃)	OR₁	OR₂	OR₃
Overall	23	0.88 (0.70-1.10)	0.87 (0.76-1.00)	1.01 (0.86-1.19)	68	36	56	NS
AA cases and NANA controls	13	0.89 (0.63-1.25)	0.90 (0.77-1.05)	1.01 (0.75-1.35)	69	23	69	NS
	10 ^b	0.67 (0.54-0.84)	0.80 (0.66-0.95)	0.90 (0.75-1.08)	10	0	10	Codominant
European	8	1.11 (0.63-1.93)	0.97 (0.76-1.22)	1.14 (0.70-1.86)	79	36	75	NS
Children	8	0.92 (0.59-1.42)	0.89 (0.73-1.10)	1.05 (0.64-1.70)	64	0	80	NS
Year of publication
2006-2010 ^c	7	0.86 (0.53-1.37)	0.84 (0.69-1.03)	0.98 (0.61-1.59)	73	0	81	NS
2001-2005	6	0.95 (0.56-1.61)	0.91 (0.65-1.28)	1.03 (0.81-1.31)	66	47	15	NS
No. of cases and controls ^d
≥ 100 cases and ≥ 100 controls	6	0.73 (0.48-1.10)	0.88 (0.64-1.23)	0.83 (0.69-1.00)	70	64	22	NS
< 100 cases or < 100 controls	7	1.15 (0.63-2.07)	0.88 (0.70-1.12)	1.34 (0.72-2.49)	69	0	78	NS
NAA cases and NANA controls	5	0.88 (0.39-1.97)	1.02 (0.67-1.57)	0.83 (0.54-1.27)	78	38	43	NS

Abbreviations: AA, atopic asthma; NAA, non-atopic asthma; NANA, non-atopic non-asthma; NS, non-significant; OR, odds ratio.
^a Guideline for interpretation of the I ² statistic: I ² = 0% no heterogeneity, I ² = 25% low heterogeneity, I ² = 50% moderate heterogeneity, and I ² = 75% high heterogeneity [17].
^b Excluding studies with excessive contribution to among-study heterogeneity identified by post-hoc sequential analysis [11, 27, 42].
^c Including the in press article at time of search by Murk et al. [4].
^d Numbers include only genotyped cases and controls.

ISSN: 1471-2350